← All trials
NCT06216301
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 31, 2024
- Primary completion
- Oct 31, 2028
- Completion date
- Oct 31, 2028
- First posted
- Jan 22, 2024
- Last posted
- Aug 14, 2024
- Enrollment
- 734
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- NovoCure GmbHLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.